Kinetics and Mechanism of the Oxidation of Thiourea by Bromate in Acidic Solution Reuben H
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Appendix a List of International Authors, Contributors, and Reviewers
APPENDIX A LIST OF INTERNATIONAL AUTHORS, CONTRIBUTORS, AND REVIEWERS COCHAIRS Ayité-Lô Nohende Ajavon Université de Lomé Togo Daniel L. Albritton National Oceanic and Atmospheric Administration US Gérard Mégie Centre National de la Recherche Scientifique France Robert T. Watson World Bank US AUTHORS AND CONTRIBUTORS CHAPTER 1 CONTROLLED SUBSTANCES AND OTHER SOURCE GASES Chapter Lead Authors Stephen A. Montzka NOAA Climate Monitoring and Diagnostics Laboratory US Paul J. Fraser CSIRO Division of Atmospheric Research Australia Coauthors James H. Butler NOAA Climate Monitoring and Diagnostics Laboratory US Peter S. Connell Lawrence Livermore National Laboratory US Derek M. Cunnold Georgia Institute of Technology US John S. Daniel NOAAAeronomy Laboratory US Richard G. Derwent UK Meteorological Office UK Shyam Lal Physical Research Laboratory India Archie McCulloch Marbury Technical Consulting UK David E. Oram University of East Anglia UK Claire E. Reeves University of East Anglia UK Eugenio Sanhueza Instituto Venezolano de Investigaciones Cientificas Venezuela L. Paul Steele CSIRO Division of Atmospheric Research Australia Guus J.M. Velders National Institute of Public Health and the Environment (RIVM) The Netherlands Ray F. Weiss University of California at San Diego/Scripps Institution US of Oceanography Rodolphe J. Zander Université de Liège Belgium Contributors Stephen O. Andersen Environmental Protection Agency US James Anderson Harvard University US Donald R. Blake University of California at Irvine US A.1 AUTHORS, CONTRIBUTORS, AND REVIEWERS Martyn P. Chipperfield University of Leeds UK Ed Dlugokencky NOAA Climate Monitoring and Diagnostics Laboratory US James W. Elkins NOAA Climate Monitoring and Diagnostics Laboratory US Andreas Engel Universität Frankfurt Germany David B. Harper The Queen's University of Belfast UK Emmanuel Mahieu Université de Liège Belgium Klaus Pfeilsticker Universität Heidelberg Germany Jean-Pierre Pommereau Service d'Aéronomie du CNRS France James M. -
Determination of Thiamazole in Tablet Formulation by Using Reversed Phase Liquid Chromatographic Method
4th International Symposium on Innovative Approaches in Engineering and Natural Sciences SETSCI Conference November 22-24, 2019, Samsun, Turkey Proceedings https://doi.org/10.36287/setsci.4.6.146 4 (6), 512-515, 2019 2687-5527/ © 2019 The Authors. Published by SETSCI Determination of Thiamazole in Tablet Formulation by Using Reversed Phase Liquid Chromatographic Method Kader Poturcu1+, Ebru Çubuk Demiralay1* 1Arts & Science Faculty, Suleyman Demirel University, Isparta, Turkey *Corresponding author: [email protected] +Speaker: [email protected] Presentation/Paper Type: Oral / Full Paper Abstract – In this study, the amount of thiamazole (methimazole) in pharmaceutical tablet formulation was determined by using reversed phase liquid chromatography method (RPLC). Chromatographic separation was carried out by using YMC Triart C18 (150 mm × 4.6 mm, 3μm, YMC, USA) column. 5% (v/v) acetonitrile-water binary mixture at pH 9.5 was used as a mobile phase. Metronidazole was chosen as an internal standard. Flow rate was 0.8 ml/min and column temperature was 25 °C in chromatographic separation. The studied wavelengths for thiamazole and metronidazole are 260 and 340 nm, respectively. This proposed method was suitably validated with respect to accuracy, precision, linearity, the limit of detection (LOD) and limit of quantification (LOQ). The calibration graph of thiamazole was linear from 4 ppm to 14 ppm. The recovery of the 5 mg thiamazole containing commercial tablet (Thyromazol) was 100.059%. The proposed RPLC method was successfully applied to the determination of thiamazole in commercial tablet formulation. Keywords –Thiamazole, tablet formulation, RPLC method, method validation, recovery. I. INTRODUCTION In the last years thiamazole became also a fashioned model substance for endocrine disruption (thyroid axis) studies thus During the last decades, there has been increasing evidence inhibits the production of the thyroid hormones. -
Gold Dissolution in Acid Thiourea-Thiocyanate Solutions Using Ferric As Oxidant
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by The University of Utah: J. Willard Marriott Digital Library University of Utah Institutional Repository Author Manuscript Thiourea-thiocyanate leaching system for gold a b b b a Xiyun Yang , Michael S. Moats , Jan D. Miller , Xuming Wang , Xichang Shi , a Hui Xu a UU IR Author Manuscript School of Metallurgical Science and Engineering, Central South University, Hunan 410083, China bDepartment of Metallurgical Engineering, College of Mines and Earth Sciences, University of Utah, Salt Lake City, Utah 84112, USA Abstract: The leaching of gold in thiourea-thiocyanate solutions has been studied by the rotating-disk technique using ferric sulfate as oxidant. The effects of initial concentrations of ferric, thiourea (Tu) and thiocyanate as well as temperature and pH values on gold leaching rates were studied. An initial gold leaching rate in the order of -9 -2 -1 10 mol cm s was obtained at 25℃, which was higher than rates obtained when either ferric-thiocyanate or ferric-thiourea solutions were used separately. The synergistic effect was attributed to the formation of a mixed ligand complex UU IR Au(Tu)2SCN. Determinations of apparent activation energy indicate that the process was controlled by a combination of chemical reaction and diffusion in the mixed lixiviant system. Open circuit potentials show that thiocyanate stability is increased in Author Manuscript the mixture. Keywords: Gold dissolution; Thiourea; Thiocyanate; Synergistic effect 1. Introduction Corresponding author:Tel.:+86 731 88877352; fax:+86 731 88710171 E-mail address:[email protected](Xiyun Yang) University of Utah Institutional Repository Author Manuscript A possible alternative reagent to cyanide for gold leaching is thiocyanate, as first reported by White (1905). -
Abstract Measurement and Analysis of Bromate Ion
ABSTRACT MEASUREMENT AND ANALYSIS OF BROMATE ION REDUCTION IN SYNTHETIC GASTRIC JUICE by Jason Dimitrius Keith Bromate ion is a possible carcinogen that is regulated by the US EPA at a Maximum Contamination Level (MCL) of 10 µg/L in drinking water. In order to propose an improved scientifically appropriate bromate ion MCL, a more rigorous scientific methodology is needed for determining low level dose health risks. The objectives of this research project were to measure bromate ion with oxidizing and/or reducing agents typically ingested in foods and drinking water. The loss of bromate ion in HCl is too slow for significant reduction in the stomach. -5 Addition of 10 M H2S, a gastric juice component, decreases the half-life from 153 to 14 minutes. The ingested reducing agents iodide ion, nitrite ion, and iron(II) decrease the lifetime of bromate ion in the stomach. Chlorine, monochloramine, and iron(III) have little actual effect on the lifetime of bromate ion. The measured rates and chemical details of the reactions are discussed. MEASUREMENT AND ANALYSIS OF BROMATE ION REDUCTION IN SYNTHETIC GASTRIC JUICE A Thesis Submitted to the faculty of Miami University in partial fulfillment of the requirements for the degree of Master of Science Department of Chemistry by Jason Dimitrius Keith Miami University Oxford, Ohio 2005 Co-Advisor________________ (Dr. Gilbert Gordon) Co-Advisor________________ (Dr. Gilbert E. Pacey) Reader_________________ (Dr. Michael W. Crowder) Reader_________________ (Dr. Hongcai Zhou) TABLE OF CONTENTS TABLE OF CONTENTS ii LIST OF TABLES iii LIST OF FIGURES iv ACKNOWLEDGEMENTS v INTRODUCTION 1 Bromate Ion Chemistry and Human Toxicology 1 Prior Analytical Methodology 6 Objectives 7 METHOD DEVELOPMENT AND ESTABLISHMENT OF PROTOCOLS 7 Solution Preparation 7 Preparation and Measurement of Stock HOCl/ Cl2 and ClNH2 Solutions 11 Measurement of Iron(II) and Iron(III) in Solution 12 Instrumentation. -
Aldrich Organometallic, Inorganic, Silanes, Boranes, and Deuterated Compounds
Aldrich Organometallic, Inorganic, Silanes, Boranes, and Deuterated Compounds Library Listing – 1,523 spectra Subset of Aldrich FT-IR Library related to organometallic, inorganic, boron and deueterium compounds. The Aldrich Material-Specific FT-IR Library collection represents a wide variety of the Aldrich Handbook of Fine Chemicals' most common chemicals divided by similar functional groups. These spectra were assembled from the Aldrich Collections of FT-IR Spectra Editions I or II, and the data has been carefully examined and processed by Thermo Fisher Scientific. Aldrich Organometallic, Inorganic, Silanes, Boranes, and Deuterated Compounds Index Compound Name Index Compound Name 1066 ((R)-(+)-2,2'- 1193 (1,2- BIS(DIPHENYLPHOSPHINO)-1,1'- BIS(DIPHENYLPHOSPHINO)ETHAN BINAPH)(1,5-CYCLOOCTADIENE) E)TUNGSTEN TETRACARBONYL, 1068 ((R)-(+)-2,2'- 97% BIS(DIPHENYLPHOSPHINO)-1,1'- 1062 (1,3- BINAPHTHYL)PALLADIUM(II) CH BIS(DIPHENYLPHOSPHINO)PROPA 1067 ((S)-(-)-2,2'- NE)DICHLORONICKEL(II) BIS(DIPHENYLPHOSPHINO)-1,1'- 598 (1,3-DIOXAN-2- BINAPH)(1,5-CYCLOOCTADIENE) YLETHYNYL)TRIMETHYLSILANE, 1140 (+)-(S)-1-((R)-2- 96% (DIPHENYLPHOSPHINO)FERROCE 1063 (1,4- NYL)ETHYL METHYL ETHER, 98 BIS(DIPHENYLPHOSPHINO)BUTAN 1146 (+)-(S)-N,N-DIMETHYL-1-((R)-1',2- E)(1,5- BIS(DI- CYCLOOCTADIENE)RHODIUM(I) PHENYLPHOSPHINO)FERROCENY TET L)E 951 (1,5-CYCLOOCTADIENE)(2,4- 1142 (+)-(S)-N,N-DIMETHYL-1-((R)-2- PENTANEDIONATO)RHODIUM(I), (DIPHENYLPHOSPHINO)FERROCE 99% NYL)ETHYLAMIN 1033 (1,5- 407 (+)-3',5'-O-(1,1,3,3- CYCLOOCTADIENE)BIS(METHYLD TETRAISOPROPYL-1,3- IPHENYLPHOSPHINE)IRIDIUM(I) -
Thyroid Hormone Regulation of Mrnas Encoding Thyrotropin β-Subunit, Glycoprotein Î
Thyroid hormone regulation of mRNAs encoding thyrotropin b-subunit, glycoprotein a-subunit, and thyroid hormone receptors a and b in brain, pituitary gland, liver, and gonads of an adult teleost, Pimephales promelas Sean C Lema, Jon T Dickey , Irvin R Schultz and Penny Swanson Abstract Thyroid hormones (THs) regulate growth, morphological transcript levels for TR isoforms a and b (tra and trb) in the development, and migratory behaviors in teleost fish, yet liver and brain, but reduced levels of brain mRNA for the little is known about the transcriptional dynamics of gene immediate-early gene basic transcription factor-binding targets for THs in these taxa. Here, we characterized TH protein (bteb). In the ovary and testis, exogenous T3 elevated regulation of mRNAs encoding thyrotropin subunits and gene transcripts for tshb, glycoprotein hormone a-subunit thyroid hormone receptors (TRs) in an adult teleost fish ( gpha), and trb, while not affecting tra levels. Taken model, the fathead minnow (Pimephales promelas). Breeding together, these results demonstrate negative feedback of T4 pairs of adult minnows were fed diets containing 3,5, on pituitary tshb, identify tra and trb as T3-autoinduced 0 3 -triiodo-L-thyronine (T3) or the goitrogen methimazole genes in the brain and liver, and provide new evidence for 10 days. In males and females, dietary intake of that tshb, gpha, and trb are THs regulated in the gonad of exogenous T3 elevated circulating total T3, while methima teleosts. Adult teleost models are increasingly used to zole depressed plasma levels of total thyroxine (T4). In both evaluate the endocrine-disrupting effects of chemical sexes, this methimazole-induced reduction in T4 led to contaminants, and our results provide a systemic assessment elevated mRNA abundance for thyrotropin b-subunit (tshb) of TH-responsive genes during that life stage. -
IRENAT 300 Mg/Ml, Solution Buvable En Gouttes
1. NAME OF THE MEDICINAL PRODUCT Irenat Drops 300 mg sodium perchlorate, oral drops Sodium perchlorate monohydrate 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution (approximately 15 drops) contains 344.2 mg sodium perchlorate monohydrate (equivalent to 300 mg sodium perchlorate) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oral drops 4. CLINICAL PARTICULARS 4.1 Therapeutic indications For the treatment of hyperthyroidism, for thyroid blockade in the context of radionuclide studies of other organs using radioactively labelled iodine or of immunoscintigraphy to detect tumours using antibodies labelled with radioiodine. For the detection of a congenital iodine organification defect (perchlorate discharge test). 4.2 Posology and method of administration Posology Adults receive 4-5 x 10 Irenat drops daily (equivalent to 800-1000 mg sodium perchlorate) or, exceptionally, 5 x 15 Irenat drops daily (equivalent to 1500 mg sodium perchlorate) as an initial dose for the first 1-2 weeks. The mean maintenance dose is 4 x 5 Irenat drops (equivalent to 400 mg sodium perchlorate) per day. Children between the ages of 6 and 14 are treated throughout with a dose of 3-6 x 1 or 4-6 x 2 Irenat drops (equivalent to 60-240 mg sodium perchlorate) daily. When used for the perchlorate discharge test following administration of the dose of radioiodine tracer, a single dose is given of 30-50 Irenat drops (equivalent to 600-1000 mg sodium perchlorate) or 300 mg-600 mg/m 2 body surface area in children. As pretreatment for radionuclide studies not involving the thyroid itself and using radioactively labelled drugs or antibodies containing iodine or technetium, Irenat drops should be administered at doses of 10 – 20 drops (equivalent to 200-400 mg sodium perchlorate) and, in isolated cases, up to 50 drops (equivalent to 1000 mg sodium perchlorate) so as to reduce exposure of the thyroid to radiation and to block uptake of radionuclide into certain compartments. -
Design, Synthesis, and Docking Study of Acyl Thiourea Derivatives As Possible Histone Deacetylase Inhibitors with a Novel Zinc Binding Group
Scientia Pharmaceutica Article Design, Synthesis, and Docking Study of Acyl Thiourea Derivatives as Possible Histone Deacetylase Inhibitors with a Novel Zinc Binding Group Duraid H. Al-Amily * and Mohammed Hassan Mohammed Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad 10047, Iraq; [email protected] * Correspondence: [email protected] Received: 1 September 2019; Accepted: 16 October 2019; Published: 22 October 2019 Abstract: Histone deacetylase inhibitors with zinc binding groups often exhibit drawbacks like non-selectivity or toxic effects. Thus, there are continuous efforts to modify the currently available inhibitors or to discover new derivatives to overcome these problems. One approach is to synthesize new compounds with novel zinc binding groups. The present study describes the utilization of acyl thiourea functionality, known to possess the ability to complex with metals, to be a novel zinc binding group incorporated into the designed histone deacetylase inhibitors. N-adipoyl monoanilide thiourea (4) and N-pimeloyl monoanilide thiourea (5) have been synthesized and characterized successfully. They showed inhibition of growth of human colon adenocarcinoma and mouse hepatoblastoma cells with low cytotoxic effect against normal human breast cells. Their binding mode to the active site of several histone deacetylases has been studied by docking and the results gave a preliminary indication that they could be successful histone deacetylase inhibitors. Keywords: histone deacetylase inhibitors; acyl thiourea derivatives; zinc binding group; distance from zinc ion 1. Introduction Histone deacetylases (HDACs) comprise a class of enzymes that catalyze the deacetylation of the "-amino groups of lysine residues at the N-termini of histones [1], proteins that act as a core for DNA compaction into nucleosomes that comprise chromatins [2]. -
Standard Thermodynamic Properties of Chemical
STANDARD THERMODYNAMIC PROPERTIES OF CHEMICAL SUBSTANCES ∆ ° –1 ∆ ° –1 ° –1 –1 –1 –1 Molecular fH /kJ mol fG /kJ mol S /J mol K Cp/J mol K formula Name Crys. Liq. Gas Crys. Liq. Gas Crys. Liq. Gas Crys. Liq. Gas Ac Actinium 0.0 406.0 366.0 56.5 188.1 27.2 20.8 Ag Silver 0.0 284.9 246.0 42.6 173.0 25.4 20.8 AgBr Silver(I) bromide -100.4 -96.9 107.1 52.4 AgBrO3 Silver(I) bromate -10.5 71.3 151.9 AgCl Silver(I) chloride -127.0 -109.8 96.3 50.8 AgClO3 Silver(I) chlorate -30.3 64.5 142.0 AgClO4 Silver(I) perchlorate -31.1 AgF Silver(I) fluoride -204.6 AgF2 Silver(II) fluoride -360.0 AgI Silver(I) iodide -61.8 -66.2 115.5 56.8 AgIO3 Silver(I) iodate -171.1 -93.7 149.4 102.9 AgNO3 Silver(I) nitrate -124.4 -33.4 140.9 93.1 Ag2 Disilver 410.0 358.8 257.1 37.0 Ag2CrO4 Silver(I) chromate -731.7 -641.8 217.6 142.3 Ag2O Silver(I) oxide -31.1 -11.2 121.3 65.9 Ag2O2 Silver(II) oxide -24.3 27.6 117.0 88.0 Ag2O3 Silver(III) oxide 33.9 121.4 100.0 Ag2O4S Silver(I) sulfate -715.9 -618.4 200.4 131.4 Ag2S Silver(I) sulfide (argentite) -32.6 -40.7 144.0 76.5 Al Aluminum 0.0 330.0 289.4 28.3 164.6 24.4 21.4 AlB3H12 Aluminum borohydride -16.3 13.0 145.0 147.0 289.1 379.2 194.6 AlBr Aluminum monobromide -4.0 -42.0 239.5 35.6 AlBr3 Aluminum tribromide -527.2 -425.1 180.2 100.6 AlCl Aluminum monochloride -47.7 -74.1 228.1 35.0 AlCl2 Aluminum dichloride -331.0 AlCl3 Aluminum trichloride -704.2 -583.2 -628.8 109.3 91.1 AlF Aluminum monofluoride -258.2 -283.7 215.0 31.9 AlF3 Aluminum trifluoride -1510.4 -1204.6 -1431.1 -1188.2 66.5 277.1 75.1 62.6 AlF4Na Sodium tetrafluoroaluminate -
Optimal 131I Therapy of Thyrotoxicosis SNMMI Annual Meeting, 6/26/2018
Optimal 131I Therapy of Thyrotoxicosis SNMMI Annual Meeting, 6/26/2018 I Love What I do, i.e. Nuclear Medicine … RADIOACTIVE IODINE THERAPY FOR No other relevant disclosures HYERTHYROIDISM Mark Tulchinsky, MD, FACNM, CCD or conflicts of interest Professor of Radiology and Medicine Division of Nuclear Medicine Penn State University Hospital Radioactive Iodine (RAI) Learning Objectives Administration for Graves’ • Treatment Options Disease: Birthplace of • Medications Radiotheranostics • Surgery Saul Hertz, M.D. • 131I Treatment (RAIT) (April 20, 1905 – July 28, 1950) • The first to study RAI in an • Graves’ Disease w/o Orbitopathy animal model of hyperthyroidism • Graves’ Disease with Orbitopathy • March 31st, 1941, at the age of 35 y, administered • Toxic Adenoma the first RAI treatment • Multinodular Toxic Goiter (RAIT) to a patient with Grave’s disease • Intermittent (recurrent) Thyroiditis • The first to use RAI uptake to inform RAIT, i.e. • Amiodarone Thyrotoxicosis radiotheranostic principle Therapeutic Options for Productive Conditions Amenable to RAIT Hyperthyroidism Condition Etiology • Antithyroid Drug therapy (ATDT) Graves’ disease (~80%) TSH-R-Ab stimulation of thyrocyte Symptomatic control with beta blockers Toxic Multinodular Goiter mutation → TSH-R-Ab activation → Toxic Adenoma autonomous function Thioureas, aka Thionamides, Anti- Hashimoto’s Thyroiditis in autoimmune disease - a variety of Thyroid Drugs (ATD’s) productive phase (“Hashi- cell- and antibody-mediated toxicosis”, overlaps Graves’) immune processes Corticosteroids -
Chemical Substances Exempt from Notification of Manufacturing/Import Amount
Chemical Substances Exempt from Notification of Manufacturing/Import Amount A list under Chemical Substance Control Law (Japan) 2014-3-24 Official issuance: Joint Notice No.1 of MHLW, METI and MOE English source: Chemical Risk Information Platform (CHRIP) Edited by: https://ChemLinked.com ChemLinked Team, REACH24H Consulting Group| http://chemlinked.com 6 Floor, Building 2, Hesheng Trade Centre, No.327 Tianmu Mountain Road, Hangzhou, China. PC: 310023 Tel: +86 571 8700 7545 Fax: +86 571 8700 7566 Email: [email protected] 1 / 1 Specification: In Japan, all existing chemical substances and notified substances are given register numbers by Ministry of International Trade and Industry (MITI Number) as a chemical identifier. The Japanese Chemical Management Center continuously works on confirming the mapping relationships between MITI Numbers and CAS Registry Numbers. Please enter CHRIP to find if there are corresponding CAS Numbers by searching the substances’ names or MITI Numbers. The first digit of a MITI number is a category code. Those adopted in this List are as follows: 1: Inorganic compounds 2: Chained organic low-molecular-weight compounds 3: Mono-carbocyclic organic low-molecular-weight compounds 5: Heterocyclic organic low-molecular-weight compounds 6: Organic compounds of addition polymerization 7: Organic compounds of condensation polymerization 8: Organic compounds of modified starch, and processed fats and oils 9: Compounds of pharmaceutical active ingredients, etc. This document is provided by ChemLinked, a division of REACH24H Consulting Group. ChemLinked is a unique portal to must-know EHS issues in China, and essential regulatory database to keep all EHS & Regulatory Affairs managers well-equipped. You may subscribe and download this document from ChemLinked.com. -
Electronic Structures and Spin Density Distributions of Bro2 and (HO)2Bro Radicals
Article pubs.acs.org/IC Electronic Structures and Spin Density Distributions of BrO2 and (HO)2BrO Radicals. Mechanisms for Avoidance of Hypervalency and for Spin Delocalization and Spin Polarization Rainer Glaser* and Cory Camasta Department of Chemistry, University of Missouri, Columbia, Missouri 65211, United States *S Supporting Information ABSTRACT: The results are reported of an ab initio study of bromine dioxide BrO2, 1, and of the T-shaped trans- and cis- dihydroxides 2 and 3 of dihydrogen bromate (HO)2BrO. The thermochemistry has been explored of potential synthetic routes to (HO)2BrO involving water addition to BrO2, hydroxyl addition to bromous acid HOBrO, 4, protonation/ − reduction of bromic acid HOBrO2, 5, via tautomers 6 8 of protonated bromic acid, and by reduction/protonation of − bromic acid via radical anion [HOBrO2] , 9. The potential energy surface analyses were performed at the MP2(full)/6- 311G* level (or better) and with the consideration of aqueous solvation at the SMD(MP2(full)/6-311G*) level (or better), and higher-level energies were computed at levels up to QCISD(full,T)/6-311++G(2df,2pd)//MP2. The addition of RO radical to bromous acid or bromite esters and the reduction of protonated bromic acid or protonated bromate esters are promising leads for possible synthetic exploration. Spin density distributions and molecular electrostatic potentials were computed at the QCISD(full)/6-311G*//MP2(full)/6-311G* level to characterize the electronic structures of 1−3. Both radicals employ maximally occupied (pseudo) π-systems to transfer electron density from bromine to the periphery. While the formation of the (3c-5e) π-system suffices to avoid hypervalency in 1, the π formation of the (4c-7e) -system in 2 or 3 still leaves the bromine formally hypervalent and (HO)2BrO requires delocalization of bromine density into σ*-SMOs over the trans O−Br−O moiety.